OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Emily Punch, Justus Klein, Patrick Diaba‐Nuhoho, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 3
Open Access | Times Cited: 56

Showing 26-50 of 56 citing articles:

Dendritic cell‐derived exosomal miR‐3064‐5p inhibits SIRT6/PCSK9 to protect the blood‐brain barrier after subarachnoid hemorrhage
Yan Wang, Long Zhang, Li Lv, et al.
Journal of Biochemical and Molecular Toxicology (2023) Vol. 37, Iss. 6
Closed Access | Times Cited: 6

COVID-19 and Lipid Disorders
Ulrich Julius, Ulrike Schatz, Sergey Tselmin, et al.
Hormone and Metabolic Research (2022) Vol. 54, Iss. 08, pp. 514-521
Closed Access | Times Cited: 9

Tissue and Serum Biomarkers in Degenerative Aortic Stenosis-Insights into Pathogenesis, Prevention and Therapy
Alkistis Kapelouzou, Styliani Geronikolou, Irene Lidoriki, et al.
Biology (2023) Vol. 12, Iss. 3, pp. 347-347
Open Access | Times Cited: 5

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
Erica Gianazza, Chiara Macchi, Cristina Banfi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 5

Proprotein convertase subtilisin/kexin type 9 inhibitor ameliorates cerebral ischemia in mice by inhibiting inflammation
Linyu Chen, Yuanyuan Du, Huimin Qiao, et al.
Journal of Stroke and Cerebrovascular Diseases (2023) Vol. 33, Iss. 2, pp. 107517-107517
Closed Access | Times Cited: 5

Association between circulatory microRNA-218 expression, serum PCSK9 levels, inflammatory markers, and monocyte subsets in coronary artery disease patients: impact of statin therapy
Dina A. Desouky, Nahla Nosair, Dalia Elsayed Sherif, et al.
Beni-Suef University Journal of Basic and Applied Sciences (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations
Fengyuan Lu, En Li, Xiaoyu Yang
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1

PCSK9 Inhibitors and Anthracyclines: The Future of Cardioprotection in Cardio-Oncology
Matthew Leonard Repp, Mark D. Edwards, Christopher S. Burch, et al.
Hearts (2024) Vol. 5, Iss. 3, pp. 375-388
Open Access | Times Cited: 1

Lipid Dynamics in Pancreatic β-Cells: Linking Physiology to Diabetes Onset
Blanka Holendová, Linda Stokičová, Lydie Plecitá‐Hlavatá
Antioxidants and Redox Signaling (2024) Vol. 41, Iss. 13-15, pp. 865-889
Closed Access | Times Cited: 1

Chemistry and biology of natural stilbenes: an update
Li‐Peng Zhou, Xinyu Cai, Ying Wang, et al.
Natural Product Reports (2024)
Closed Access | Times Cited: 1

Protective effect of evolocumab on Müller cells in the rat retina under hyperglycaemic and hypoxic conditions
Qing Zhou, Huan Tang, Shuting Li
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 10, pp. 108593-108593
Closed Access | Times Cited: 4

Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Vanessa Bianconi, Giacomo Cafaro, Massimo R. Mannarino, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1384-1384
Open Access | Times Cited: 2

Current Medical Therapy and Revascularization in Peripheral Artery Disease of the Lower Limbs: Impacts on Subclinical Chronic Inflammation
Andrea Leonardo Cecchini, Federico Biscetti, Matteo Manzato, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16099-16099
Open Access | Times Cited: 2

RNA interference-based therapies for the control of atherosclerosis risk factors
Sanna Kettunen, Anna‐Kaisa Ruotsalainen, Seppo Ylä‐Herttuala
Current Opinion in Cardiology (2022) Vol. 37, Iss. 4, pp. 364-371
Open Access | Times Cited: 3

PCSK9 inhibition in myeloid cells enhances cardioprotection beyond its LDL cholesterol-lowering effects
Shin Hye Moon, Hyo Won Ki, Na Hyeon Yoon, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access

Mitigating Vascular Inflammation by Mimicking AIBP Mechanisms: A New Therapeutic End for Atherosclerotic Cardiovascular Disease
Jun‐Dae Kim, Abhishek Jain, Longhou Fang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10314-10314
Open Access

PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagy
Qian Zhang, Mengdan Miao, Shan‐Hu Cao, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 742, pp. 151081-151081
Open Access

Mechanisms underlying the effects of the conditional knockdown of hepatic PCSK9 in attenuating lipopolysaccharide-induced acute liver inflammation
Miao Miao, Xueying Zhang, Haiyan Yu, et al.
International Journal of Biological Macromolecules (2024), pp. 139066-139066
Closed Access

Pathophysiologie der Atherosklerose
Roman N. Rodionov, Natalia Jarzebska, Henning Morawietz, et al.
Springer Reference Medizin (2024), pp. 1-29
Closed Access

Increased PCSK9 associated with cIMT in AS: A useful marker for subclinical atherosclerosis in patients with ankylosing spondylitis
Ahmet Karakoyun, Yasemin Akkubak, Mevlüt Hakan Göktepe, et al.
Archives of Rheumatology (2024) Vol. 39, Iss. 4, pp. 652-661
Open Access

Immune Homeostasis Maintenance Through Advanced Immune Therapeutics to Target Atherosclerosis
Shuo Geng, Yajun Wu, Liwu Li
Methods in molecular biology (2024), pp. 25-37
Closed Access

Scroll to top